In the October 2016 issue of the JEVT, Thompson et al 1 report the early and midterm results of the EVAS FORWARD Global Registry. In this multicenter experience, 277 patients were treated with the Nellix Endovascular Aneurysm Sealing System (Endologix Inc, Irvine, CA, USA). The authors observed a persistent endoleak rate of 0.7% (1 type Ia and 1 type II) at 1 year, with freedom from types I and II endoleaks of 96.3% and 98.2%, respectively. Those results are particularly interesting as the registry contained an anatomically more challenging cohort compared to the GREAT and ENGAGE registries. 2, 3 What attracts even more attention, though, is a closer look at the percentages of patients treated beyond the instructions for use (IFU). In that regard, both the GREAT and the ENGAGE registries share similar numbers of patients (17% and 18%, respectively) treated beyond the IFU. In the EVAS FORWARD registry, however, close to 37% of patients were treated beyond the IFU, more than double the rates of GREAT and ENGAGE. This finding leads to an obvious question: Why is it that Nellix was implanted so many times beyond the IFU? Shouldn't one be extremely cautious with a new stent-graft that is still lacking long-term results? Even more so, given the fact that said stent-graft employs a quite different method of excluding the aneurysm?
At the beginning, too little attention was paid to proximal neck length, resulting in either landing too low, giving away precious proximal landing zone, or implanting Nellix in <10mm proximal necks; we now take a very close look at the proximal neck. As suggested by Thompson and colleagues 1 after analyzing the type Ia endoleaks in the EVAS FORWARD registry, technical errors, such as low landing, seem to be responsible, an observation with which we agree. Hence, in order to avoid type Ia endoleak, it appears to be important to land as closely as possible to the renal arteries. We believe that this is likely to result in a different scenario of flow dynamics, potentially lowering the pressure burden exerted by the pulse wave onto the endobags. In necks <10 mm and/ or highly laden with thrombus, we prefer to combine Nellix with renovisceral chimney grafts to create a sufficient landing zone of at least 10 mm.
As for the treatment of type I endoleaks, Thompson et al 1 report 4 early and 4 late type I endoleaks treated with coil embolization and liquid embolic agents to create a proximal seal between the aortic wall and the endobags. 6, 7 Taking into account the likely underlying pathogenesis of type I endoleaks, namely, low stent-graft deployment, this approach seems questionable, since it fixes only the symptoms and not the pathology apparently responsible for it. In the abovementioned scenarios, we prefer the Nellix-in-Nellix application (NINA) to liquidate the endoleak. Using NINA, one creates the landing zone that should have been achieved in the primary implantation. Once again, if necessary, we combine NINA with renovisceral chimney grafts. While our initial and midterm results with NINA are promising, long-term data are essential to determine the durability and hence the validity of this treatment.
To conclude, in line with the preliminary outcomes of the EVAS FORWARD registry, 1 we think that the concept of aneurysm sealing is a promising one with acceptable results. However, great caution must be taken both preoperatively and operatively to avoid complications. Just because the stent-graft comes with an endobag, one must not forget the principles of endovascular aortic repair. As usual, time and more data are necessary to determine the place of any new innovation in the armamentarium of endovascular therapy.
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